Total Live Articles: 488

Substance Use Disorder

Department of Health and Social Care Guidance Drug misuse and dependence: UK guidelines on clinical management. Last updated: Aug 2026.

Substance Use Disorder

This article covers:

  • Substance use disorder as a whole
  • Commonly misused substances, including:
    • Cocaine
    • Cannabis
    • MDMA (ecstasy)
    • LSD
    • Ketamine

Substance Use Disorder Overview

Risk Factors

[Ref]

  • Family history of substance use disorder
  • Concurrent mental health conditions, esp.
    • Depression and other mood disorders
    • Anxiety disorders
    • ADHD
    • Psychotic disorders
    • Personality disorders
  • Childhood adversity and trauma
  • Environmental and social factors (e.g. exposure to substance use within the family or peer group, socioeconomic disadvantage and stressful living environments)
  • Early initiation of substance use
  • Greater availability and exposure to substances

Diagnostic Criteria

High-yield pattern recognition for substance use disorder:

Substance use disorder should be considered when substance use becomes persistent and problematic, causing:

  • Loss of control → using more than intended, unsuccessful attempts to cut down, craving, or spending substantial time obtaining/using/recovering from the substance
  • Impaired functioning → problems at work, education, home or in relationships; reducing or giving up important activities
  • Continued use despite harm → recurrent or continued use despite recognised physical or psychological consequences
  • Physiological adaptationtolerance and/or withdrawal

NB Diagnosis does not require all 4 patterns, see below for more details.

DSM-5 criteria for substance use disorder require≥2 of the 11 criteria occurring within the same 12-month period: [Ref]

Criteria Description
Impaired control over substance use
  • Consuming the substance in larger amounts and for a longer amount of time than intended
  • Persistent desire to cut down or regulate use. The individual may have unsuccessfully tried to stop in the past
  • Spending a great deal of time obtaining, using, or recovering from the effects of substance use
  • Experiencing craving, a pressing desire to use the substance
Social impairment
  • Substance use impairs ability to fulfil major obligations at work, school, or home
  • Continued use of the substance despite it causing significant social or interpersonal problems
  • Reduction or discontinuation of recreational, social, or occupational activities because of substance use
Risky use
  • Recurrent substance use in physically unsafe environments
  • Persistent substance use despite knowledge that it may cause or exacerbate physical or psychological problems
Pharmacologic
  • Tolerance: Individual requires increasingly higher doses of the substance to achieve the desired effect, or the usual dose has a reduced effect; individuals may build tolerance to specific symptoms at different rates
  • Withdrawal: A collection of signs and symptoms that occurs when blood and tissue levels of the substance decrease, individuals are likely to seek the substance to relieve symptoms
    • NB there is no characteristic withdrawal syndrome for hallucinogens, phencyclidine and inhalants, therefore the withdrawal criterion generally cannot be met for those substances
NB Tolerance and withdrawal in the context of appropriate medical treatment (i.e. pain medication used as prescribed) do NOT count as criteria

Severity is then based on the total number of the criteria met:

  • Mild: 2–3 criteria
  • Moderate: 4–5 criteria
  • Severe: ≥6 criteria

UK Controlled Drug Classification

Under the Misuse of Drugs Act 1971, controlled drugs are classified as Class A, B or C according to their assessed potential harm to the individual and society

  • Class A → generally considered the most harmful and carries the highest legal penalties
  • Class B → intermediate classification
  • Class C → generally considered lower harm than Class A or B and carries lower penalties

NB This is a legal classification and should not be used alone to determine the clinical toxicity or severity of intoxication in patients [Ref]

Class Common examples
A
  • Cocaine
  • MDMA (ecstasy)
  • Methamphetamine (crystal meth)
  • Heroin
  • Fentanyl
  • LSD
  • Magic mushrooms
B
  • Cannabis
  • Amphetamine
  • Keatmine
  • Codeine
  • Methylphenidate
  • GHB / GBL
  • Barbiturates
C
  • Benzodiazepines
  • Pregabalin / gabapentin
  • Buprenorphine
  • Anabolic steroids
  • Nitrous oxide

High-Yield Substances

Alcohol

Alcohol use disorder (including alcohol withdrawal, alcohol misuse) is covered separately in a dedicated article as it is clinically important and has distinct intoxication, withdrawal and management pathways.

See the Alcohol Use Disorders article.

Opioids

Opioid misuse (including opioid intoxication, opioid withdrawal) is covered separately in a dedicated article as it is clinically important and has distinct intoxication, withdrawal and management pathways.

See the article.

Opioids are a drug class, not one specific drug

  • However, “opioid” is a pharmacological class, not a Class A/B/C category
  • For instance, heroin, fentanyl and methadone are Class A, while codeine is Class B

Common examples include:

  • Morphine
  • Codeine
  • Fentanyl
  • Oxycodone
  • Heroin (diamorphine)

Opiates vs opioids

  • Opiates = naturally derived from opium, e.g. morphine and codeine
  • Opioids = broader term covering natural, semi-synthetic and synthetic opioid drugs, e.g. heroin, fentanyl, methadone

Cocaine

Domain Subcategory Key information
Overview [Ref] Common names / examples There are 2 main forms of cocaine:

  • Powder cocaine (cocaine hydrochloride) → usually snorted (less commonly injected)
  • Crack cocaine (free-based cocaine) → usually smoked
Drug class / MoA Drug class: CNS / sympathomimetic stimulant

MoA:

  • Primarily inhibits presynaptic monoamine reuptake (esp. dopamine)
    • ↑ Dopamine → euphoria and reinforcing / addictive effects
    • ↑ Noradrenaline → sympathetic  effects
  • Also inhibits voltage-gated sodium channels (→ local anaesthetic effects)
Acute effects [Ref]

Intoxication / expected acute effects

CNS stimulant / dopaminergic effects:

  • Euphoria
  • Increased alertness
  • Increased energy
  • Reduced appetite
  • Feeling powerful / confident
  • May progress to agitation / hyperstimulation

Sympathomimetic effects:

  • Tachycardia
  • Hypertension
  • Mydriasis
  • Diaphoresis
  • Hyperthermia
Acute toxicity / overdose features Neuropsychiatric:

  • Severe anxiety
  • Agitation / aggression
  • Seizures
  • Delirium / acute psychosis (e.g. hallucinations, delusions)

Cardiovascular:

  • Coronary vasospasm → myocardial ischaemia +/- infarction
  • Severe hypertension
  • Stroke
  • Aortic dissection
  • Arrhythmias

Systemic and other:

  • Hyperthermia
  • Rhabdomyolysis
  • Intestinal ischaemia
  • Severe toxicity may lead to renal failure and coagulopathy

Cocaine toxicity is usually a clinical diagnosis

  • Urine toxicology screen serves as a confirmatory test
  • Serum cocaine levels are typically NOT measured and not required for diagnosis
  • Additional investigations for cocaine-related chest pain
    • Suspected myocardial ischaemia: serial ECG, troponin, chest X-ray)
    • Suspected aortic dissection: ECG, chest X-ray, CT chest)

General initial toxicology work-up:

  • Metabolic panel (U&Es, bone profile)
  • Blood gas, including lactate level
  • Serum paracetamol, salicylate and ethanol concentrations
  • Urinalysis and urine toxicology screen
Acute management

There is no antidote for cocaine, management is targeted at symptoms

Mild intoxication usually requires NO treatment due to the short half-life of cocaine

Management for more severe intoxication:

  • Severe agitation / hypertension / seizures → benzodiazepines
    • Consider IV nitrates / nicardipine if hypertension persists despite benzodiazepines
  • Hyperthermia → IV fluids, active cooling, sedation
  • Suspected myocardial ischaemia should be managed as acute coronary syndrome

Avoid beta blockers in acute cocaine toxicity

Long-term effects [Ref] Complications from chronic use
  • Repeated intranasal use → nasal septal perforation
  • Cardiomyopathy
  • Cognitive impairment
  • Interstitial pneumonitis / pulmonary fibrosis (from frequent inhalation of contaminated cocaine)
Withdrawal features  

Withdrawal symptoms develop quickly as cocaine has a short half-life:

  • Post-cocaine “crash”
  • Somnolence
  • Difficulty concentrating
  • Increased appetite
Long-term management There is no medication to treat cocaine dependence or withdrawal symptoms

Mainstay is psychosocial interventions:

  • Contingency management (incentives for abstinence) – strongest evidence
  • CBT
  • Community reinforcement approach
  • Family, couples and social network interventions
  • Peer groups

Manage any comorbid conditions (e.g. depression)

Cannabis

Domain Subcategory Key information
Overview [Ref] Common names / examples Cannabis is a psychoactive drug derived from the Cannabis plant

Weed (marijuana) is a specific type of cannabis preparation, which is dried cannabis plant material

Drug class / MoA Cannabis contains multiple cannabinoids, which are chemicals that act on the cannabinoid system

  • THC is the main psychoactive / intoxicating cannabinoid (i.e. the main intoxicating component)
  • THC acts as a partial agonist at cannabinoid CB1 and CB2 receptors
    • CB1 receptors are mainly expressed in the CNS
    • Activation of CB1 receptors alters neurotransmitter release → affects mood, perception, memory, coordination and appetite
Acute effects [Ref]

Intoxication / expected acute effects

Psychological / CNS effects

  • Euphoria and relaxation
    • The characteristic “high” with cannabis use is relaxation / dreamy / altered perception
    • Rather than marked stimulation seen with stimulant drugs
  • Altered time, colour and spatial perception
  • Impaired concentration, reaction time, fine coordination
  • Increased appetite
  • Anxiety, panic or paranoia may occur (esp. in inexperienced users)

Physical effects

  • Tachycardia
  • Conjunctival injection
  • Dry mouth
Acute toxicity / overdose features Acute cannabis toxicity is usually mild and self-limiting

Mainly causes neuropsychiatric effects

  • Marked anxiety
  • Paranoia
  • dysphoria
  • Psychotic symptoms may be precipitated or exacerbated (esp. in susceptible individuals)

High doses in young children may cause respiratory depression

Acute management Most patients require observation and supportive care only

Management of hyperemesis syndrome

  • IV fluids + antiemetics
  • Definitive management = cessation of cannabis use
Long-term effects [Ref] Complications from chronic use
  • Cannabinoid hyperemesis syndrome (recurrent / cyclical episodes of nausea and vomiting)
  • Respiratory
    • Chronic cough
    • Wheeze
    • Increased sputum
    • Recurrent acute bronchitis
  • Cognitive impairment +/- hippocampal structural changes
  • Reduced fertility
  • Chronic heavy use is associated with risk of
    • Psychotic disorders (e.g. schizophrenia)
    • Depression, anxiety
    • Other substance use disorder
Withdrawal features Cannabis withdrawal is usually mild and may occur after stopping frequent, heavy use:

  • Insomnia
  • Irritability
  • Depression
  • Nausea
  • Reduced appetite
Long-term management There is no medication to treat cannabis dependence or withdrawal symptoms

Mainstay is psychosocial interventions:

  • Less dependent users → brief motivational interventions
  • Heavily dependent users → structured care-planned intervention
    • Motivational enhancement
    • CBT
    • Contingency management (incentives for abstinence)

Manage any comorbid conditions (e.g. depression)

MDMA (Ecstasy)

MDMA vs ecstasy vs methamphetamine vs crystal meth

Domain Subcategory Key information
Overview [Ref] Common names / examples MDMA = 3, 4-methylenedioxymethamphetamine

Common recreational names:

  • Ecstasy (often marketed as tablets)
  • Molly (often marketed as powder / crystals)
Drug class / MoA Class: substituted amphetamine with stimulant and empathogenic effects

MoA: increases pre-synaptic monoamine neurotransmitter concentrations

  • Serotonin (prominent effect) → mood elevation, altered perception, empathogenic effects
  • Dopamine → stimulant / reward effects
  • Noradrenaline → sympathetic effects

Do not confuse related amphetamine-type drugs:

  • Amphetamine = a stimulant drug (e.g. dexamfetamine used for ADHD)
  • Methamphetamine (meth / crystal meth) = a related stimulant with predominantly dopaminergic and noradrenergic effects
  • MDMA (ecstasy / molly) = a related substituted amphetamine with more prominent serotonergic effects
Acute effects [Ref]

Intoxication / expected acute effects

Neuropsychiatric effects

    • Excitement and disinhibition
    • Increased empathy and feelings of interpersonal closeness
    • Heightened physical sensation
    • Euphoria
    • Difficulty concentrating
    • May cause a sense of ego dissolution

 

    (feeling “at one” with the world)

Sympathetic effects

  • Tachycardia
  • Hypertension
  • Mydriasis
  • Hyperthermia
Acute toxicity / overdose features
  • SIADH → hyponatraemia
    • Severe hyponatraemia may cause cerebral oedema → altered mental status and seizures
  • Sympathomimetic toxicity
    • Tachycardia, tachyarrhythmias, hypertension
    • Hyperthermia
    • Agitation, hyperactivity, seizures
  • Hyperthermia-related complications
    • Rhabdomyolysis
    • Multiorgan failure
    • Coagulopathy

MDMA toxicity is typically a clinical diagnosis

Important investigations:

  • ECG + cardiac monitoring
  • Serum sodium level (if hyponatraemia is present → paired serum + urine osmolality + urine sodium)
  • Renal function

Serum MDMA concentration is rarely required

General initial toxicology work-up:

  • Metabolic panel (U&Es, bone profile)
  • Blood gas, including lactate level
  • Serum paracetamol, salicylate and ethanol concentrations
  • Urinalysis and urine toxicology screen
Acute management
  • Benzodiazepines (IM / IV) for agitation, tachycardia, hypertension, seizures
  • External cooling for hyperthermia
  • Isotonic IV fluids for hyponatraemia (severe hyponatraemia may require hypertonic saline) and rhabdomyolysis
Long-term effects [Ref] Complications from chronic use
  • Dependence
  • Cognitive decline
  • Paranoid psychosis
Long-term management There is no medication to treat MDMA dependence or withdrawal symptoms

Mainstay is psychosocial interventions

LSD (Lysergic Acid Diethylamide)

LSD is a classic hallucinogen

Domain Subcategory Key information
Overview [Ref] Common names / examples LSD = lysergic acid diethylamide

Common recreational name: acid

Drug class / MoA Class: semi-synthetic classic hallucinogen (psychedelic)

Primary MoA: 5-HT (serotonin) receptor agonist

Acute effects [Ref]

Intoxication / expected acute effects

Neuropsychiatric effects

  • Altered perception with intensification of sensations (e.g. intensified colours, distorted vision)
  • Synesthesia (e.g. “seeing sounds” or “hearing colours”)
  • Altered sense of reality
  • Depersonalisation (feeling that the self is unreal)
  • Mood changes (usually euphoria, but may be depressive)
  • Impaired judgement

Despite LSD being classed as a hallucinogen, true hallucinations and delusions are uncommon, perceptual distortion is more typical.

Physical effects

  • Mydriasis
  • Blurred vision
  • Sweating
  • Palpitations
  • Impaired coordination
Acute toxicity / overdose features Severe LSD toxicity is uncommon

Neuropsychiatric

  • Severe anxiety
  • Extreme apprehension or agitation
  • Delusions or true hallucinations

Systemic

  • Hyperthermia
  • Tachyarrhythmia
  • Cardiovascular instability in massive overdose
Acute management Most cases: observation in a quiet, calming environment + reassurance 

Consider benzodiazepines for severe anxiety / agitation

External cooling + benzodiazepines for hyperthermia

Long-term effects [Ref] Complications from chronic use Hallucinogen persistent perception disorder (HPPD) / “flashbacks”

  • Recurrent perceptual disturbances after the drug has been stopped
  • Usually involves visual illusions, but can also involve distortions of
    • Other senses
    • Self-image
    • Time
    • Space
Withdrawal features No characteristic withdrawal syndrome is recognised

Physical dependence is not a typical feature of LSD use

Long-term management Mainstay is psychosocial interventions

No medications

Ketamine

Domain Subcategory Key information
Overview [Ref] Common names / examples Common recreational names include ket and K
Drug class / MoA Class: dissociative anaesthetic agent

MoA: NMDA glutamate receptor non-competitive antagonist

Acute effects [Ref]

Intoxication / expected acute effects

Neuropsychiatric effects

  • Inappropriately elevated mood
  • Dissociation (feeling detached from oneself or the environment)
  • Depersonalisation
  • Altered responses to external stimuli

Physical effects

  • Nystagmus
  • Tachycardia
Acute toxicity / overdose features
  • Marked dissociation + depersonalisation
  • Seizures
  • Coma
  • Tachycardia, severe hypertension, arrhythmias
  • Hyperthermia
  • Acidosis
  • Laryngospasm
Acute management Most cases: supportive care (keep in a quiet, calming environment) + close observation

Benzodiazepines for agitation or seizures

Long-term effects [Ref] Complications from chronic use
  • Ketamine cystitis (“ketamine bladder”)
    • Dysuria
    • Urinary frequency
    • Haematuria
  • Biliary colic
  • Memory impairment
Withdrawal features No characteristic withdrawal syndrome is recognised
Long-term management Mainstay is psychosocial interventions

No medications

References

Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Stay Updated withGuideline Genius

Sign up to be notified when our newsletter launches, covering major guideline updates, article updates, and future UKMLA resources.